| Company Name: |
Hubei Xinyang Medical Technology Co., Ltd
|
| Tel: |
15347293736 |
| Email: |
2853117764@qq.com |
| Products Intro: |
Product Name:Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl-
CAS:1254032-16-0
Purity:99% HPLC Package:10mg;25mg;50mg;100mg;200mg;500mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:AR-13503
CAS:1254032-16-0
Package:25mg/RMB 13900;50mg/RMB 18300;100mg/RMB 23500
|
| Company Name: |
commedx
|
| Tel: |
010-46598925 18519000250 |
| Email: |
zhanghu@commedx.com |
| Products Intro: |
CAS:1254032-16-0
Purity:95% HPLC
|
Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- manufacturers
- AR-13503
-
- $1970.00 / 25mg
-
2025-10-27
- CAS:1254032-16-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Basic information |
| | Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Chemical Properties |
| Boiling point | 649.2±55.0 °C(Predicted) | | density | 1.310±0.06 g/cm3(Predicted) | | pka | 12.89±0.43(Predicted) | | form | Solid | | color | White to off-white |
| | Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Usage And Synthesis |
| Uses | (rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2]. | | in vivo | AR-13503 (1.25 mg/kg; i.p.; once daily for 5 days) in collaboration with Aflibercept (HY-108801), significantly decreases the development of aberrant neovascularization (NV)[1].
| Animal Model: | Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)[1] | | Dosage: | 1.25 mg/kg | | Administration: | Intraperitoneal injection; once daily for 5 days | | Result: | The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%). |
| | References | [1] Ding J, et al. ROCK/PKC inhibitor AR-13503 inhibits angiogenesis and protects the barrier function of retinal pigment epithelium[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 205-205.
[2] Carbajal K, et al. AR-13503 Enhances the efficacy of aflibercept in a mouse model of proliferative diabetic retinopathy[J]. Investigative Ophthalmology & Visual Science, 2018, 59(9): 200-200. |
| | Benzeneacetamide, α-(aminomethyl)-4-(hydroxymethyl)-N-6-isoquinolinyl- Preparation Products And Raw materials |
|